| Tao, Rong |
TOUCH, NCT04425070: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma |
|
|
| Active, not recruiting | 1/2 | 56 | RoW | ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab | Antengene Corporation | Peripheral T-cell Lymphoma, NK/T-cell Lymphoma | 12/24 | 12/24 | | |
|
|
|
NCT05577364: Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients |
|
|
| Recruiting | 1/2 | 54 | RoW | Selinexor, exportin 1 (XPO1) inhibitor, R-CHOP Protocol, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone | Sun Yat-sen University, Fudan University, Antengene Corporation | EBV-Positive Diffuse Large B-Cell Lymphoma, Nos | 12/24 | 02/26 | | |
NCT05186012: APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1/2 | 51 | RoW | APG-1252, Pelcitoclax, Chidamide | Ascentage Pharma Group Inc. | NHL, Adult | 09/25 | 03/26 | | |
TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
|
|
| Terminated | 1 | 20 | RoW | ATG-019, KPT-9274, ATG-019 + Niacin ER | Antengene Therapeutics Limited | Solid Tumor, Non-Hodgkin's Lymphoma | 10/23 | 10/23 | | |
| Recruiting | 1 | 48 | RoW | KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells） | Rong Tao, Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent | 10/26 | 12/26 | | |
| Sun, Xin |
NCT05092841: A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A |
|
|
| Completed | 3 | 176 | RoW | PXT3003, (RS)-baclofen, naltrexone hydrochloride and D-sorbitol oral fixed dose combination, PXT3003 placebo, liquid oral solution | Tasly GeneNet Pharmaceuticals Co., Ltd | Charcot-Marie-Tooth Type 1A | 03/24 | 03/24 | | |
NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1/2 | 63 | RoW | SPH4336, Cadonilimab | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 05/25 | 12/25 | | |
| Liu, Chuanxu |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
